Skip to main content

Table 8 Follow-up data after PG-116800 withdrawal in patients with clinically significant shoulder findings and hand adverse events

From: Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

 

Level of recovery

Number of patients

Mean time (days)

Median time (days)

Minimum time (days)

Maximum time (days)

Comments

Shoulder

Complete

10

122

81

5

316

Additional 3 patients recovered while still on drug

 

Partial

3

107

138

30

154

Additional 3 patients recovered while still on drug

 

Unchanged vs. baseline

0

     

Hand

Complete

2

224

224

163

285

 
 

Partial

12

210

213

93

329

 
 

Unchanged vs. baseline

7

196

184

77

303

 

Both

Complete

0

     
 

Partial

2

170

170

79

261

Additional 1 patient recovered while still on drug

 

Unchanged vs. baseline

0